Key result
An 83-year-old man developed severe pulmonary veno-occlusive disease after 6 months of gemcitabine therapy for metastatic pancreatic cancer, which improved with symptomatic treatment.
Population
1 83-year-old man with metastatic pancreatic cancer
Design
Case_report
Follow-up
6 months to onset of symptoms, plus unspecified follow-up…
Authors
Loading...
Clinicians should monitor for PVOD in gemcitabine recipients with dyspnea; this novel association leaves open the need for confirmatory studies.
Case Report (n=1)
Gemcitabine therapy may induce severe pulmonary toxicities, including pulmonary veno-occlusive disease, which can be managed with symptomatic treatment.
Turco et al. (2015) conducted a case report in Metastatic pancreatic cancer (n=1). Gemcitabine was evaluated on Pulmonary veno-occlusive disease (PVOD). An 83-year-old man developed severe pulmonary veno-occlusive disease after 6 months of gemcitabine therapy for metastatic pancreatic cancer, which improved with symptomatic treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: